18F-FDOPA PET Imaging in Prolactinoma

Ginet, Merwan; Cuny, Thomas; Schmitt, Emmanuelle; Marie, Pierre-Yves; Verger, Antoine

doi:10.1097/rlu.0000000000001721

Cited by 12 publications

(4 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Few positive findings have been reported in a large series of NEN patients consisting of multiple myeloma, hepatocellular carcinoma, schwannoma and chondrosarcoma. 27 Intense tumor 18 F-FDOPA uptake has also been described in case reports of squamous cell carcinoma, 28 poorly differentiated adenocarcinoma, 29 thyroid neoplasms of follicular origin, 30 (Figure 4) prolactinoma, 31 and melanoma. 32 Melanoma case reports can be explained by the high AADC expression which is involved in melanin biosynthesis.…”

Section: Pathological Conditionsmentioning

confidence: 73%

Variants and Pitfalls of PET/CT in Neuroendocrine Tumors

Impériale

Meuter

Pacák

et al. 2021

Seminars in Nuclear Medicine

View full text Add to dashboard Cite

Section: Pathological Conditionsmentioning

confidence: 73%

Variants and Pitfalls of PET/CT in Neuroendocrine Tumors

Impériale

Meuter

Pacák

et al. 2021

Seminars in Nuclear Medicine

View full text Add to dashboard Cite

“…An interesting alternative approach to imaging D2Rexpressing lactotroph tumors has been identified through a small number of case reports using 18 F-DOPA as a ligand. Here, it is speculated that DOPA enters dopaminergic cells in the arcuate nucleus of the hypothalamus and is converted and secreted into the cleft between dopamine-secreting neurons and lactotroph cells (42,43).…”

Section: Smentioning

confidence: 99%

Using Molecular Imaging to Enhance Decision Making in the Management of Pituitary Adenomas

et al. 2021

View full text Add to dashboard Cite

In most patients with suspected or confirmed pituitary adenomas (PAs), MRI, performed using T1-(with or without gadolinium enhancement) and T2-weighted sequences, provides sufficient information to guide effective clinical decision making. In other patients, additional MR sequences (e.g., gradient recalled echo, fluid-attenuation inversion recovery, MR elastography, or MR angiography) may be deployed to improve adenomadetection, assess tumoral consistency, or aid distinction from other sellar/parasellar lesions (e.g., aneurysm, meningioma). However, there remains a small but important subgroup of patients in whom primary or secondary intervention (e.g., first or redo transsphenoidal surgery, stereotactic radiosurgery) is limited by the inability of MRI to accurately localize the site(s) of de novo, persistent, or recurrent PA. Emerging evidence indicates that hybrid imaging, which combines molecular (e.g. 11 C-methionine PET) and cross-sectional (MRI) modalities, can enable the detection and precise localization of sites of active tumor to guide targeted intervention. This not only increases the likelihood of achieving complete remission with preservation of remaining normal pituitary function but may mitigate the need for long-term (even lifelong) high-cost medical therapies. Here, we review published evidence supporting the use of molecular imaging in the management of PAs, including our own 10-y experience with 11 C-methionine PET.

show abstract

“…However, dopaminergic imaging has rarely been studied in prolactinomas. Only 11 C-N-methylspiperone, 11 Craclopride, 18 F-FDOPA and 18 F-fallypride as PET tracers have been used in prolactinomas [13][14][15]. Due to its convenience and stability, 18 F-fallypride has recently been successfully tested as a PET tracer to study prolactinomas [15].…”

Section: Introductionmentioning

confidence: 99%

DRD2 expression based on 18F-fallypride PET/MR predicts the dopamine agonist resistance of prolactinomas: a pilot study

Tang

Cheng

et al. 2023

Endocrine

View full text Add to dashboard Cite

The dopamine agonists (DA) have been used widely to treat prolactinomas. However, it is di cult to predict whether the patient will be responsive to DA treatment. MethodsWe aimed to investigate whether the in vivo expression of DRD2 based on 18 F-fallypride PET/MR could predict the therapeutic effect of DA on prolactinomas.Seven patients with prolactinomas who underwent surgery and further tumor immunohistochemistry completed 18 F-fallypride PET/MR preoperatively. Imaging ndings and immunohistochemical staining were compared with treatment outcomes. Results18 F-fallypride PET/MR was visually positive in 7 of 7 patients, and DRD2 target speci city could be con rmed by immunohistochemical staining. A signi cantly lower tracer standard uptake value (SUV) could be detected in the resistant patients (n = 3) than in the sensitive patients (n = 4; SUV mean , 4.67 ± 1.32 vs. 13.57 ± 2.42, p < 0.05). DRD2 expression determined by 18 F-fallypride PET/MR corresponded with the DA treatment response. Conclusion18 F-fallypride PET/MR represents an effective diagnostic tool to predict DA response in patients with prolactinoma.

show abstract

18F-FDOPA PET Imaging in Prolactinoma

Cited by 12 publications

References 8 publications

Variants and Pitfalls of PET/CT in Neuroendocrine Tumors

Variants and Pitfalls of PET/CT in Neuroendocrine Tumors

Using Molecular Imaging to Enhance Decision Making in the Management of Pituitary Adenomas

DRD2 expression based on 18F-fallypride PET/MR predicts the dopamine agonist resistance of prolactinomas: a pilot study

Contact Info

Product

Resources

About